03287nas a2200253 4500000000100000008004100001260002300042653002500065653002000090653001800110653002200128100001300150700001300163700001600176700001100192700001600203700001100219245013300230856026000363300000700623490000600630520238300636022001403019 2020 d bF1000 Research Ltd 10 aEconomic evaluations 10 aschistosomiasis 10 aInterventions 10 aSystematic review 1 aTurner H 1 aFrench M 1 aMontresor A 1 aKing C 1 aRollinson D 1 aToor J 00 aEconomic evaluations of human schistosomiasis interventions: a systematic review and identification of associated research needs uhttps://d212y8ha88k086.cloudfront.net/manuscripts/17277/b5751d60-66b4-44a8-b89b-a96d22c698e0_15754_-_hugo_turner.pdf?doi=10.12688/wellcomeopenres.15754.1&numberOfBrowsableCollections=4&numberOfBrowsableInstitutionalCollections=0&numberOfBrowsableGateways= a45 0 v5 3 aBackground: Schistosomiasis is one of the most prevalent neglected tropical diseases (NTDs) with an estimated 229 million people requiring preventive treatment worldwide. Recommendations for preventive chemotherapy strategies have been made by the World Health Organization (WHO) whereby the frequency of treatment is determined by the settings prevalence. Despite recent progress, many countries still need to scale up treatment and important questions remain regarding optimal control strategies. This paper presents a systematic review of the economic evaluations of human schistosomiasis interventions. Methods: A systematic review of the literature was conducted on 22nd August 2019 using the PubMed (MEDLINE) and ISI Web of Science electronic databases. The focus was economic evaluations of schistosomiasis interventions, such as cost-effectiveness and cost-benefit analyses. No date or language stipulations were applied to the searches. Results: We identified 53 relevant health economic analyses of schistosomiasis interventions. Most studies related to Schistosoma japonicum followed by S. haematobium. Several studies also included other NTDs. In Africa, most studies evaluated preventive chemotherapy, whereas in China they mostly evaluated programmes using a combination of interventions (such as chemotherapy, snail control and health education). There was wide variation in the methodology and epidemiological settings investigated. A range of effectiveness metrics were used by the different studies. Conclusions: Due to the variation across the identified studies, it was not possible to make definitive policy recommendations. Although, in general, the current WHO recommended preventive chemotherapy approach to control schistosomiasis was found to be cost-effective. This finding has important implications for policymakers, advocacy groups and potential funders. However, there are several important inconsistencies and research gaps (such as how the health benefits of interventions are quantified) that need to be addressed to identify the resources required to achieve schistosomiasis control and elimination. a2398-502X